NOSIUM (NOSIUM ) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
6 Jun, 2025Executive summary
Q1 2025 marked by strategic focus on structural deals and investment opportunities, with ongoing evaluation of new business prospects after ending reverse acquisition talks with Brasseriegruppen.
Market conditions in Sweden remain challenging but offer opportunities for companies with active acquisition agendas.
Financial highlights
Group net revenue for Q1 2025 was 1,345 TKR, down 39% year-over-year; parent company net revenue was 79 TKR, up 509% due to invoiced services to subsidiaries.
Group operating result improved to -864 TKR from -2,359 TKR; parent company operating result improved to -546 TKR from -1,168 TKR.
Group net result attributable to parent shareholders was -1,130 TKR (vs. -3,375 TKR); parent company net result was -712 TKR (vs. -2,374 TKR).
Cash flow from operating activities improved to -839 TKR (group) and -518 TKR (parent), reflecting cost reductions.
Outlook and guidance
NOSIUM continues to pursue strategic investments and structural deals, with ongoing dialogues with unlisted companies aiming for public listing.
Management sees favorable market conditions for executing a major transaction in 2025.
Latest events from NOSIUM
- 2025 saw declining revenue and losses amid a strategic shift to medtech via the Medicortex merger.NOSIUM
Q4 202520 Feb 2026 - Positive Q3 results and a transformative medtech acquisition mark a pivotal quarter.NOSIUM
Q3 202527 Nov 2025 - Cost reductions and divestments improved results amid ongoing strategic transformation.NOSIUM
Q2 202528 Aug 2025 - Sharp revenue decline and major restructuring, including a reverse acquisition and share issue.NOSIUM
Q3 202413 Jun 2025 - Sharp revenue drop offset by improved equity and new capital; cost cuts and divestments ongoing.NOSIUM
Q2 202413 Jun 2025 - Sharp revenue drop and asset write-downs, but improved equity and cost control.NOSIUM
Q4 20246 Jun 2025